Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M44.0Revenue (TTM) $M0.9Net Margin (%)-6,452.3Altman Z-Score-4.8
Enterprise Value $M8.5EPS (TTM) $-2.2Operating Margin %-6,255.0Piotroski F-Score4
P/E(ttm)--Beneish M-Score-3.2Pre-tax Margin (%)-6,452.3Higher ROA y-yN
Price/Book2.210-y EBITDA Growth Rate %--Quick Ratio3.0Cash flow > EarningsY
Price/Sales32.45-y EBITDA Growth Rate %--Current Ratio3.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-94.1Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M41.3ROIC % (ttm)-4,997.5Gross Margin Increase y-yN

Gurus Latest Trades with ARGS

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

ARGS is held by these investors:

ARGS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Pharmstandard International S.10% Owner 2016-10-07Buy31,704$4.73-74view
Pharmstandard International S.10% Owner 2016-09-29Buy43,618$4.56-73.03view
Pharmstandard International S.10% Owner 2016-09-20Buy46,839$4.77-74.21view
Pharmstandard International S.10% Owner 2016-09-16Buy52,512$4.77-74.21view
Pharmstandard International S.10% Owner 2016-09-01Buy16,977$4.78-74.27view
Pharmstandard International S.10% Owner 2016-08-24Buy67,371$4.52-72.79view
Pharmstandard International S.10% Owner 2016-08-24Buy55,224$4.57-73.09view
Pharmstandard International S.10% Owner 2016-08-22Buy75,474$4.24-70.99view
Winterbottom JoanChief Human Resources Officer 2015-12-16Buy250$1.83-32.79view
Petrov Andrei VladimirovichDirector 2015-12-16Buy5,000$1.8-31.67view

Quarterly/Annual Reports about ARGS:

    News about ARGS:

    Articles On GuruFocus.com
    Investment Strategies for the Bullish Biotech Sector Jun 01 2015 
    Weekly 3-Year Low Highlights: VCRA, CLUB, ARGS, ONTX, BOTA Jun 08 2014 

    More From Other Websites
    Biotech Movers And Shakers: Ocular Therapeutix Inc (OCUL) And Argos Therapeutics Inc (ARGS) Feb 23 2017
    Committee Suggests Argos Halt Cancer Drug Study Feb 23 2017
    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Argos... Feb 22 2017
    Argos Therapeutics, TripAdvisor Enter Wednesday’s 52-Week Low Club Feb 22 2017
    Argos stock sinks more than 65 percent following recommendation to stop trial Feb 22 2017
    Argos Therapeutics downgraded by FBR & Co. and JMP Securities Feb 22 2017
    Argos Therapeutics Tanks on Committee Suggestion to Stop Carcinoma Drug Study Feb 22 2017
    Argos says independent committee predicts trial failure, shares slump Feb 22 2017
    Argos Plummets 72%, Leads Biotech Movers Feb 22 2017
    Argos says independent committee suggests stopping carcinoma study Feb 22 2017
    Argos Therapeutics cancer treatment study recommended to be discontinued for futility Feb 22 2017
    ARGOS THERAPEUTICS INC Files SEC form 8-K, Other Events Feb 22 2017
    Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial... Feb 22 2017
    Argos Therapeutics to Participate in 2017 Genitourinary Cancers Symposium Feb 13 2017
    Is the Options Market Predicting a Spike in Argos Therapeutics (ARGS) Stock? Feb 06 2017
    Argos Therapeutics to Participate in BIO CEO and Investor Conference Feb 06 2017
    ARGOS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Jan 23 2017
    Argos CEO talks commercialization and hiring following expansion Jan 23 2017
    Argos Therapeutics Completes Lease Agreement for Commercial Manufacturing Space on the Centennial... Jan 19 2017
    Argos Therapeutics (ARGS) Looks Good: Stock Rises by 5% Jan 06 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)